Overall survival between BMI groups.

BackgroundComplete cytoreductive surgery with Hyperthermic intraperitoneal chemotherapy (HIPEC) is the standard treatment for patients with peritoneal metastases. In this retrospective observational two-center study, we assessed the impact of patient’s body mass index (BMI) on surgical and oncological outcomes.MethodsBetween 2017 and 2021, 144 patients with peritoneal metastases (all etiologies) were included. Morbi-mortality at day-30, overall survival and free-recurrence-survival were compared according to the patients BMI. The patients were divided into 2 groups (BMI ResultsMedian overall survival (OS) was 71.3 months [63–71.5], with significant differences observed between BMI groups (p = 0.015). Recurrence-free survival (RFS) averaged 26.8 months [20–35.3] and did not significantly differ between groups (p = 0.267). After stratification by histology, OS and RFS remained consistent. Cox multivariate analysis adjusted for Peritoneal Carcinomatosis Index (PCI) revealed BMI ConclusionsOur study suggests a potential ‘obesity paradox’ in the context of HIPEC procedures. Morbidity at day-30 was similar for BMI